The blood-brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.
INTRODUCTION
face protein, and tight junction protein expression are all pathologies of the BBB in both AD and PD. Also, given its importance in separating the central and peripheral Alzheimer's disease (AD) and Parkinson's disease (PD) are common, progressive neurodegenerative dis-compartments, BBB dysfunction may play a greater than anticipated role in pathogenesis, etiology, and treatment. eases afflicting the aged. Both diseases involve selective degeneration in a limited number of areas within the In this review, we will evaluate recent literature in BBB pathology as it relates to AD and PD and discuss impli-brain. Neuroinflammation, another common feature in AD and PD, results in activated microglia and the pro-cations of BBB dysfunction in regards to therapeutics. duction of free radicals and proinflammatory cytokines.
BLOOD-BRAIN BARRIER Additionally, both diseases are characterized by the accumulation of abnormal inclusions in the affected cells.
The BBB is the key mediator between the peripheral circulation and the central nervous system (CNS). It func-These common characteristics have led to innumerable hypotheses about etiopathogenesis, susceptibility, and tions to regulate ion balance, facilitate nutrient transport, and provide a barrier from potentially harmful mole-treatment. Current drug regimens treat AD and PD symptomatically by increasing the primary neurotransmitter cules. In 1904 Paul Ehrlich described the first experimental evidence for the BBB. Ehrlich injected water-deficiency. Treatment in AD replaces acetylcholine, while treatment in PD replaces dopamine.
soluble dyes into the circulatory system, staining all organs except the brain, and attributed this phenomenon Recently, evidence has shown that both diseases may also share dysfunction in the blood-brain barrier (BBB).
to the low affinity of the dye (32) . Subsequent experiments showed that there was actually a barrier between However, implications of this dysfunction have not been widely appreciated. Altered transport mechanisms, sur-the periphery and brain, because injection of dye directly into the cerebrospinal fluid (CSF) stained all cell types line-derived neurotrophic factor (GDNF), fibroblast growth factor-β (FGF-β), and interleukin-6 (IL-6) en-in the brain but failed to penetrate the periphery (45). Following these studies, it was widely believed that hance expression of endothelial cell signaling proteins, such as tyrosine kinase receptors, and transport proteins nothing could penetrate the BBB unless there was a specific transport mechanism or the molecule was highly such as P-glycoprotein and GLUT-1 (1) . Tight junction proteins are also induced by astrocytic factors leading to lipophilic, allowing diffusion through the BBB. Therefore, the BBB was viewed as a static, impenetrable tight junction formation and enhanced barrier function (1, 12, 43, 49) . Pericytes are in close proximity to the cap-structure, in which the function could only be disrupted in severe pathology such as stroke.
illary wall and are involved in capillary contraction and further regulate endothelial cell growth, integrity, and Capillary vessels of the BBB consist of a monolayer of endothelial cells that are different from those of the migration through the production of TGF-β (31, 54) . Both the pericytes and endothelial cells are ensheathed peripheral vascular system. The endothelial cells of the BBB contain an increased number of mitochondria (86) , by the basement membrane, a membrane approximately 30-80 nm thick, composed of collagen type IV, heparin lack fenestrations (37) , have minimal pinocytotic activity (102) , and form tight junctions (61) . Endothelial sulfate proteoglycans, laminin, fibronectin, and other extracelluar matrix proteins (34) . The basement membrane cells, astrocytes, and pericytes work together to form the "neurovascular unit," which is essential for function, is involved in providing mechanical support and controlling communication between the endothelial cells and support, and formation of the BBB (Fig. 1 ).
The astrocytic end feet envelop the capillary walls, the parenchyma. Though not a part of the "neurovascular unit," neurons also play a critical role in the matura-allowing transport of nutrients between endothelial cells and the parenchyma. Factors released from astrocytes, tion of the BBB by the release of unknown factors and, in adults, are often in close proximity to endothelial cells such as transforming growth factor-β (TGF-β, glial cell Figure 1 . Illustration of the neurovascular unit of the BBB. The neurovascular unit is comprised of astrocytes, pericytes, and endothelial cells that work together to maintain and develop the characteristic nature of the BBB. The endothelial cells are joined by the tight junctions depicted above, which reduce paracellular transport. The neurovascular unit interacts with cells within the parenchyma, such as neurons and resident microglia cells. EC, endothelial cell; PC, pericyte; BM, basement membrane; ZO, zona occuldin.
forming cell-cell contacts capable of regulating barrier thelial cell (42) . BBB endothelial cells also contain cytoplasmic and organelle associated enzymes including function (12) .
On a cellular level, a critical feature of barrier func-members of the cytochrome P-450 system, monoamine oxidase, aromatic amino acid decarboxylase, and others tion is the tight junctions that link adjacent endothelial cells and restrict paracellular diffusion of water-soluble that metabolize molecules upon entry into the cell (97) . These restrictive physical and chemical characteristics substances into the brain. Tight junctions are comprised of occludins, claudins, and junctional adhesion proteins serve to protect the brain from the effects of drugs, toxins, and peripheral vascular components that could po-( Fig. 1 ). Scaffolding proteins zona occludin (ZO)-1, ZO-2, and ZO-3 interact with occludins, allowing for the tentially be harmful. On the other hand, the barrier can be a hindrance in delivering drugs that would otherwise transmembrane tight junction proteins to be linked to the actin filaments of the cytoskeleton (61, 97, 107, 119) . The be useful in treating CNS diseases. It is well known that the BBB can be disrupted in proteins of the basement membrane interact with receptors on the capillary endothelium to influence the integ-certain conditions. Bacterial meningitis, HIV, and ischemia are all known to disrupt the barrier (56,112,114). rity of tight junction (12) . BBB endothelial cells contain a high number of mitochondria that are thought to pro-Physical trauma also disrupts the barrier, although it is usually reestablished within 10 days (91) . Barrier integ-vide the energy required to develop high-resistance tight junctions (90) . As a result, resistance of the BBB is rity has also been intentionally disrupted. Administering an osmotic diuretic, such as mannitol, dehydrates endo-greater than 1000 Ω/cm 2 , which is approximately 50-100 times tighter than peripheral microvessels (1, 28) .
thelial cells, placing strain on the tight junctions that can temporarily allow paracellular entry of chemotherapeu-On a functional level, the BBB provides both a physical and chemical barrier (Fig. 2) . The physical barrier is tic agents in the treatment of brain cancer (60) . In addition, it is now known that deregulation of the junctional primarily a consequence of tight junctions that restrict passive diffusion of macromolecules and entry of pe-proteins leads to enhanced permeability. Claudin-5 knockout mice or downregulation of claudin-1 resulted ripheral vascular elements, including monocytes, immunoglobulins, and complement from entering the brain in an increase in paracellular permeability of small molecules (67, 85) . Taken together, the emerging evidence (107); the basement membrane and the astrocytic end foot processes that envelop the capillaries also contrib-suggests that the BBB may not be a static structure, but rather a dynamic structure influenced by and responding ute. The BBB endothelium contains a greater number of P-glycoprotein transporters on the luminal surface when to factors and signals not only in the brain parenchyma, but also in the periphery. Moreover, the notion that the compared with the peripheral endothelium contributing to the physical barrier (42) . P-glycoprotein extrudes integrity of the BBB is homogenous within the brain has recently been challenged. In diabetes, the midbrain was molecules back into the lumen upon entry into the endo- Figure 2 . Diagram of the transport mechanisms of the BBB. Paracellular and transcellular transport, depicted by dotted arrows, are limited in the BBB. The lack of pinocytotic vesicles and fenestrations and the presence of tight junctions require the BBB endothelial cells to express specific transporters for shuttling nutrients, such as glucose and amino acids, into the brain. Water is transported into the brain via aquaporins. Gases, however, due to their small size, can cross the BBB via passive diffusion as do highly lipophilic molecules. Other molecules, such as iron, can enter the brain via receptor-mediated endocytosis. EC, endothelial cell. the first area to show an enhanced leakage to sucrose, amyloid, leading to deposition into blood vessel membranes (128) . Normally, transporter mechanisms of the followed by hippocampus, cortex, and basal ganglia, whereas other regions showed no change in permeability BBB, such as P-glycoprotein and the LDL receptor, extrude excess β-amyloid protein. However, if transporters after 90 days (52). Such regional variation is consistent with work showing complex temporal and regional alter-are altered due to disease, then β-amyloid accumulates (7) . Accumulation of β-amyloid leads to microglia acti-ations in BBB transporters in the CNS (5) . If the BBB is a dynamic and heterogeneous structure, then it is not vation, producing reactive oxygen species, complement proteins, and proinflammatory cytokines. This leads to surprising that a growing literature has demonstrated that disrupted function in the BBB in the areas affected neurotoxicity and causes tau hyperphosphorylation (108). Hyperphosphorylated tau is more likely to cluster into in AD and PD may play a role in pathogenesis and disease progression.
aggregates creating NFTs.
Although the cause of AD is unknown, AD patients ALZHEIMER'S DISEASE with genetic mutations have led to several etiological Clinical and Neuropathological Characteristics hypotheses. The TNF-α gene polymorphic region −308A has been associated with an earlier age of onset of AD, AD is the most common disease related to dementia in the elderly, comprising 50-60% of all dementia cases implicating a neuroinflammatory component (69) . Mutations in the amyloid precursor protein genes presenilin (14). At onset, the symptoms appear to be those of normal aging such as mild forgetfulness affecting short-term 1 and presenilin 2 have been implicated in the familial form of AD as well (14). Another gene identified with memory. However, as the disease progresses, long-term memory is affected, leading to difficulty remembering late-onset AD is the ApoE allele. Though ApoE is required in cholesterol transport, about 15% of people events, activities, names of familiar people or things, and interference with activities of daily living.
have a splice variant that increases the risk of AD (44) . The variant form of ApoE is responsible for β-amyloid AD is pathologically characterized by extracellular senile plaques, intracellular neurofibrillary tangles (NFTs), deposition in vessel walls and plaque formation (14). Given the global distribution of these proteins, the ques-loss of acetylcholine neurons, cerebral amyloid angiopathy, and degeneration of cerebrovasculature in cortical tion remains as to why any of these mutations would lead to the specific neuropathology seen in AD, suggest-vessels (47) . Neuritic plaques and NFTs are found in the medial temporal lobe and cortical areas of the brain ing that these mutations are, at best, risk factors. (108). In accordance with the neuroinflammatory hy-BBB Alterations in AD pothesis, the proinflammatory effects of apolipoprotein E (ApoE), tumor necrosis factor-α (TNF-α), and inter-BBB disruption is now a widely accepted characteristic of AD. A proposed mechanism suggests that BBB leukin-1β (IL-1β) all of which are elevated in AD patients, have been implicated in AD pathology and dis-disruption is, in part, due to the build-up of β-amyloid in the vasculature, leading to proinflammatory and cyto-ease progression (95) . If inflammatory responses were occurring in AD, it would be expected that anti-inflam-toxic events. In addition to altered β-amyloid transporter function, AD subjects also have reduced numbers of matory responses would also be triggered. Elevated levels of TGF-β1), an immunosuppressive cytokine, has low-density lipoprotein receptor-related proteins in their neurovasculature, a proposed efflux transporter of βbeen observed in CSF of AD patients (96, 125) . TGF-β1 has also been found in plaques and neurofibrillary tan-amyloid (104) . β-Amyloid deposition also results in perturbation of claudin-5 organization within the tight gles in AD postmortem tissue, suggesting a role in AD pathology (115, 123) . In transgenic mice, the overexpres-junction (73). Marco et al. investigated the mRNA expression of tight junction proteins following β-amyloid sion of TGF-β1 by astroglia cells promoted cerebrovascular amyloidosis (123) . Further research confirmed deposition and discovered an increase in the amount of claudin-1 and a decrease in ZO-1 and occludin mRNA cerebrovascular amyloidosis in transgenic mice, but also demonstrated that TGF-β1 reduced plaque load and am- (73) . Bolton et al. observed breakdown of the occludin and ZO-1 protein as well as reorganization of the actin yloid burden in the brain, suggesting a role in amyloid clearance (122) . In humans, CSF levels of TGF-β1 in-filaments that anchor the tight junctions from within the cell (16). These studies suggest that β-amyloid deposi-versely correlate with CSF levels of β-amyloid in AD patients, suggesting that TGF-β1 may play a role in am-tion leads to up-or downregulation of tight junction proteins that are likely to contribute to BBB dysfunction yloid metabolism, promoting amyloid clearance, or deposition or both (125).
in AD. Despite the broadly recognized neurovascular pathol-As a consequence of aging, β-amyloid clearance becomes less effective or there is an overproduction of βogy in AD, the BBB was once believed to be intact. An early study by Alafuzoff et al. showed that the BBB was the brain. Thus, neuroinflammation-induced barrier breakdown may compromise the brain's "immune privilege" compromised to the same degree in both AD with senile dementia and nondemented elderly (2) . Results followed status, thereby potentially involving the peripheral immune response in disease progression. showing no IgG in the CSF of either early onset AD or AD with senile dementia subjects when compared to Though it is well established that there is an inflammatory response in the brain to β-amyloid load and neu-CSF of subjects with multiple infarcts, but no comparisons were made with normal aged-matched controls ronal loss, the role of the peripheral immune system is only now being investigated. In AD, there is a vigorous (79) . These studies indicated that there was not a global disruption of the BBB. However, even the early study activation of the complement system in the absence of antibodies. Rogers et al. demonstrated that aggregates of by Alafuzoff et al. observed that IgG and complement proteins were found aggregated near plaques (2), indi-β-amyloid act as a strong complement activator (93) . Damaged neuronal processes have been shown to have cating a possible focal or subtle change in permeability. Evidence for BBB disruption has now emerged demon-C5b-9, the lytic complement macromolecule, inserted into their external membranes (118) . In addition, tangles strating increased permeability of serum protein into the brain parenchyma, evidence of irregular basement mem-and plaques are clearly marked with complement fragments C4d and C3d (75) . In an animal model of AD, brane, and changes in protein expression on the BBB endothelium (57). Ultrastructural microvascular changes TGF-β was shown to increase the number of T cells in the brain (18). T cells have also been found to be acti-were observed in animals with compromised barrier function, and Skoog and colleagues suggested that bar-vated in postmortem human brain tissue of AD patients and have been suggested to contribute to disease pathol-rier dysfunction precedes dementia (26, 106) . A recent study also showed thinning and discontinuities within ogy (113) . Parachikova et al. observed elevated mRNA sequences for a number of inflammatory markers includ-the vascular basement membrane associated with leakage of the plasma protein prothrombin across the BBB ing IgG, CD14 (lipopolysaccharide receptor), toll-like receptor-2, major histocompatibility complex (MHC) II, in AD postmortem human brain tissue samples (127). Albumin, insulin, and human β-amyloid were also found and MHC I in the prefrontal cortex and hippocampus in patients with mild to moderate AD dementia (87). to be permeable through the BBB in the double transgenic Alzheimer mouse (APP, PS1) (89). This evidence Significantly higher concentrations of MHC II protein were also observed in mild to moderate dementia and implies a breakdown in barrier integrity that is consistent with the existence of neuroinflammation in the AD these proteins were colocalized with reactive microglia in the hippocampus (87). These studies suggest that brain, because inflammation is a well-known disruptor of BBB function.
there is a peripheral immune response to the inflammatory events occurring in the AD brain, implicating BBB The neuroinflammation observed in AD is likely to play a pivotal role in disease progression, possibly by breakdown. Although peripheral T cells and macrophages overexpress macrophage inflammatory protein 1α on affecting barrier function. In vitro models of the BBB have shown that β-amyloid induces release of proin-their cell surface, allowing them to use this receptor to cross the BBB (72), it cannot be discounted that barrier flammatory cytokines from microglia, leading to formation of fibrils (120) . When microglia are isolated from integrity may be compromised to the point where peripheral cells can enter areas of significant neuroinflam-postmortem brain tissue, they can phagocytose exogenous amyloid fibrils but are unable to degrade them mation paracellularly. Cytokines can regulate endothelial cell surface pro- (77) . In addition, ultrastructural analysis revealed microglia clustered around amyloid deposits in human brain teins, leading to the entry of immune cells into the brain (Fig. 3 ). TNF-α, IL-1β, and interferon gamma (INF-γ) tissue, and these clusters were incapable of effectively removing deposited amyloid, leading to increased pro-elevated intracellular adhesion molecule-1 (ICAM-1) expression, a receptor required for leukocyte extravasa-duction of proinflammatory cytokines, which can perpetuate the initial problem (94) . The proinflammatory tion and migration, on the endothelium through the activation of AP-1 and NF-κB (33,41). Upregulation of cytokines TNF-α and IL-1β, which are elevated in AD, are also well-known disruptors of BBB integrity in sep-ICAM-1, V-CAM, and E-selectin mRNA has been shown to occur after TNF-α stimulation in an in vitro sis (71). It is possible that these proinflammatory cytokines could directly lead to BBB dysfunction, contribut-BBB model system (82) . ICAM-1 is also present in high concentrations on senile plaques (116). Frohman et al. ing further to β-amyloid burden. The continued β-amyloid burden results in chronic microglial activation and pro-have shown that neuritic plaques have an increased ICAM-1 expression in AD allowing immune cells to tar-duction of proinflammatory mediators within the brain, some of which attract peripheral immune cells to enter get the plaque (41) . These studies suggest that elevated 290 DESAI ET AL. Figure 3 . Illustration of the alterations in cells within the neurovascular unit and parenchyma in response to neurodegenerative disease. In AD and PD, activated astrocytes and microglia release many cytokines. Cells within the neurovascular unit also release numerous cytokines, all of which influence neighboring cells as well as the tight junctions between endothelial cells and protein expression within cells. ICAM-1 protein expression within endothelial cells increases and tight junction proteins rearrange after exposure to cytokines, allowing peripheral immune cells to cross the BBB. EC, endothelial cell; PC, pericyte; BM, basement membrane; ZO, zona occuldin.
ICAM-1 expression can facilitate immune cell migration
Many cytokines and proteins also have angiogenic properties. VEGF is a major regulator of blood vessel into areas of inflammation and degeneration.
Cytokines and other insults including lipopolysaccha-formation and function and has been detected in CSF of AD patients (110) . Enhanced VEGF staining is observed ride, TNF-α, IL-1β, IFN-γ, vascular endothelial growth factor (VEGF), and fibroblast growth factor-2 (FGF2) around perivascular astrocytes and endothelial cells walls of the BBB in AD subjects compared to controls alter transporter expression on the endothelial cells. Kalaria et al. reported a decrease in the number of glucose (58) . Yang and colleagues have shown colocalization of VEGF and amyloid on endothelial cell walls, suggesting transporters in specific regions of the brain in AD subjects, including the frontal and temporal neocortex and that cerebrovascular pathology may play a significant role in the neurodegenerative cascade of AD (124) . We hippocampus (59) . Reports have followed showing a decrease in the number of glucose transporters, specifically have recently shown elevated number of angiogenic vessels as well as an increased total number of vessels in GLUT-1 and GLUT-3, in AD patients. Because GLUT-1 and GLUT-3 mRNA remain unchanged, it was pro-specific regions of the brain of AD postmortem human tissue, suggesting that the pathology is region specific posed that the reduction in glucose transporter is due to proinflammatory cytokine-mediated protein degradation (29) . New, immature vessels contain holes throughout the endothelium allowing for growth and migration of (81,105). Hartz et al. have shown that TNF-α reduced P-glycoprotein-mediated efflux in rat brain capillaries endothelial cells. These holes provide an avenue for drugs and toxins to enter without regulation, further sup-(48). Given that P-glycoprotein is involved in removing β-amyloid and many individuals, especially those with porting the notion that barrier integrity is compromised in AD patients. The improvement seen in AD symptoms AD, have polymorphisms of the protein (117), dysfunction in P-glycoprotein may be involved in the increase after drug treatment may be due to entry of drugs through a compromised BBB, possibly due to immature deposition of β-amyloid on vasculature, a mechanism that has been implicated in the pathogenesis of AD (117) . vessels, tight junction abnormalities, or altered transport mechanisms. A compromised BBB can also change drug tive disorder that usually affects individuals after 60; however, cases have been reported of individuals diag-bioavailability and result in adverse side effects or altered drug efficacy.
nosed with PD at younger than 40 years of age. The clinical features of PD are tremor, rigidity, bradykinesia, AD Drug Therapy and postural instability. Even though there are drugs on the market for treat-PD is pathologically characterized by loss of dopaing AD symptoms, they have limited benefits (46). Curmine neurons in the substantia nigra pars compacta rently, the only drugs approved for alleviating AD (SNpc) accompanied by inclusion bodies rich in αsymptoms are acetylcholine esterase (AChE) inhibitors.
synuclen called Lewy bodies. PD symptoms do not de-AChE inhibitors-tacrine, donepezil, rivastigmine, and velop until after a 70-80% reduction of dopamine in galantamine-are often prescribed for the management the striatum, which is associated with a 50-60% loss of of mild/moderate dementia in AD; however, patients exdopaminergic neurons in the SNpc. Degeneration also hibit lack/loss of efficacy over time (98) . Nonsteroidal occurs in other brain regions such as the locus coeruleus, anti-inflammatory drugs (NSAIDs), though not FDA apthe nucleus basalis of Meynert, the dorsal motor nucleus proved to use in AD treatment, have been shown to reof the vagus, and the pedunculopontine nucleus, as well duce β-amyloid burden in mice; however, the limited as the raphé nuclear group (13) . efficacy may be due to efflux mechanisms of the BBB Currently, 11 gene mutations from familial clusters (14). A clinical trial for rofecoxib, a selective COX-2 of PD have been identified in a small percentage of PD inhibitor, showed disappointing results due to the drug patients. Proteins encoded by these genes include parkin, efficacy in patients with advanced pathology, even α-synuclen, PTEN-induced kinase 1, DJ-1, ubiquitin though AD transgenic mice showed a decrease in βcarboxyl-terminal esterase L1, and leucine-rich repeat amyloid (14). Some studies reported COX-2 inhibition kinase 2 (35) . Although genetic alterations are risk facled to hippocampal neuron death (4), while others inditors for the disease, the precise molecular and biochemicated that COX-2 inhibition is neuroprotective (83).
cal processes governing the selective and progressive Recently, immunization with β-amyloid or passive degeneration of the nigrostriatal dopaminergic pathway immunization with antibodies against β-amyloid has in PD are poorly understood. In the absence of known been shown to reduce microgliosis, neurtic dystrophy, etiology, environmental toxins have also been impliearly tau pathology, reverses learning and memory deficated as a cause of PD (23). Several mechanisms of neucits, and restoring BBB morphology in animal models ronal death in PD have been proposed, including pro- (30) . The β-amyloid vaccine may be effective not only duction of free radicals, excitotoxicity, and activation of because of its ability to transport into the brain via the microglial and astrocytes leading to the release of proinβ-amyloid receptor, but may also enter paracellularly flammatory cytokines. TNF-α and IL-1β are found in because of disrupted tight junctions (88). Other researchsignificantly high concentrations in both animal models ers are investigating delivering metal chelators into the of PD and CSF of human patients (8) . As in AD, TNFbrain because AD patients tend to have higher concenα can lead to the production of nitric oxide, which can trations of metals in the parenchyma, leading to free raddirectly damage neurons and change BBB permeability ical formation and enhanced neuronal degeneration (99) . (53, 78) . Nanoparticles containing metal chelators employ the BBB Alterations in PD transferrin receptor to cross the BBB and reduce oxidative stress (70) . The success of nanoparticles may be, in Although a number of CNS diseases are associated part, due to their ability to diffuse through disrupted with compromised BBB function, it is widely believed tight junctions. BBB disruption in AD patients would that this is not the case in PD. Early assessment of BBB open the window for alternative therapeutic strategies integrity in PD showed no change in the blood-CSF because drug lipophilicity or presence of drug transport barrier function in PD patients, suggesting an intact systems may not be a prerequisite for treatment. More-BBB (50). Further investigation by Kurkowska-Jastrzebover, if the BBB disruption in AD is regionally specific, ska et al. showed that the dopamine neurotoxin 1then targeted delivery to areas of pathology can be methyl-1,4-phenyl-1,2,3,6-tetrahydropyrdine (MPTP) does achieved.
not disrupt BBB function in animals (64) . Even though they showed that IgG was restricted within the blood PARKINSON'S DISEASE vessel lumen, mononuclear cells had infiltrated the sub-Clinical and Neuropathological Characteristics stantia nigra and striatum, suggesting the presence of neuroinflammation, a known BBB disruptor. Canudas et PD is the most common movement disorder in the elderly and the second most common degenerative neu-al. injected MPP + into the left SN of rats, producing a small lesion, and assessed BBB integrity in the striatum rological disorder. PD is a progressive neurodegenera-292 DESAI ET AL.
with a crude index of BBB integrity (albumin staining)
Microglia have been found in high concentration in areas of neuronal degeneration in animal models of PD that may have missed small areas of BBB injury (19) . It is also important to note that these animal studies were (111). In 1988, McGeer and colleagues observed an activation of the microglia in SN and striatum of PD pa-not designed to assess BBB integrity, but were peripheral to the focus of the work. Regardless, it is likely that tients (76) . In the years that followed, several studies performed on the cerebrospinal fluid and during post-the main reason the BBB is thought to be intact in PD patients is because of the use of peripheral aromatic mortem analysis in parkinsonian patients revealed increased levels of cytokines, suggesting the activation of amino acid decarboxylase (AAAD) inhibitors.
The fact that the widely used AAAD inhibitors, car-a proinflammatory response (94, 109, 111) . Moreover, Langston et al. described the presence of active microg-bidopa and benserazide, do not "appear" to compromise levodopa therapy contributes to the belief that the BBB lia in the SN of three patients who had been exposed to MPTP several years prior to death (65) . Barcia el al. saw is intact in PD. Carbidopa was developed based on its inability to cross the BBB while effectively inhibiting activated microglia present 1 year after MPTP treatment in monkeys (11) . These results suggest that the inflam-the peripheral decarboxylase enzyme and thereby increasing availability of levodopa to the brain (92) . If matory response may be self-sustaining, inducing an imbalance that could perpetuate and/or accelerate neuronal barrier function is compromised in PD, maybe a small amount of carbidopa or benserazide leaks into the SN death over a period of years (10). TNF-α knockout in mice did not result in BBB dysfunction or microglia ac-and striatum of PD patients, reducing the potency of levodopa that would be otherwise greater if barrier function tivation even in the presence of MPTP-induced dopamine neuron loss, suggesting that BBB dysfunction is a was intact. Recent studies by Jonkers et al. (55) and Shen et al. (103) revealed that benserazide can enter the consequence of neuroinflammation and not cell death (126). brain and affect levodopa metabolism. We have also shown that benserazide levels were significantly higher Proinflammatory cytokines released by activated microglia can induce protein rearrangement and alter pro-in the ipsilateral striatum of a 6-hydroxydopaminelesioned rats relative to the unlesioned side (unpublished tein expression in tight junctions (Fig. 3 ). There is limited research on protein alterations in tight junctions or data), suggesting that benserazide enters the lesioned side of the brain more readily. We have also demon-on the endothelial cell surface in PD. Increased levels of TNF-α, IL-1β, and IL-6 in the brain have been shown strated that domperidone, a dopamine antagonist that does not cross the BBB, was able to inhibit dopamine-to decrease ZO-1 and occludin proteins in tight junctions (121) . TNF-α has also been found to decrease transen-mediated behavior (apomorphine-induced stereotypic behavior) when administered systemically to 6-hydroxy-dothelial electrical resistance by increasing the permeability of the tight junctions in an in vitro BBB model dopamine-lesioned rats (24) . Kortekaas et al. reported an 18% increase in the brain uptake of [ 11 C]verapamil, system (28, 121) . ICAM-1 is increased on the endothelium and appeared on microglia in the injured regions a drug that normally does not cross the BBB, in the mesencephalon of PD patients, relative to aged controls of an MPTP model of PD (64) . ICAM-1-is also detected on reactive astrocytes in the SN of patients with neuro-(62). This increase may have reflected alterations in Pglycoprotein or simply increased paracellular diffusion pathologically confirmed PD (80). In PD SNpc, these ICAM-1-positive reactive astrocytes were particularly into the brain. Taken together, these data suggest that peripheral AAAD inhibitors, as well as other drugs that concentrated around remaining neurons in areas of heavy neuronal loss and extracellular melanin accumula-normally do not enter the brain, enter after insult suggesting BBB breakdown. tion (80). These studies suggest that ICAM-1 facilitates immune cell migration into areas of inflammation and In addition to drug entry, researchers observed permeability of FITC-labeled albumin, horseradish peroxi-degeneration via paracellular mechanisms due to tight junction protein alterations. dase, and Evans blue into the SNpc and striatum after 6-hydroxydopamine insult in rats (24, 66) . Interestingly, As in AD, cytokines alter transport protein expression, leading to BBB permeability. PD patients have a the leakage seen in these animals was punctate, such that numerous small areas of leakage were observed through-high correlation between reduced P-glycoprotein expression and increased risk of PD (51) . Mice lacking P-out the nigrostriatal pathway. The same pattern of leakage was observed in MPTP-treated mice (126) and was glycoprotein show an elevated accumulation of pesticides and other harmful toxic substances in the brain prevented after treatment with minocycline, a microglial activation inhibitor. Additionally, areas of FITC-labeled (101), indicating the importance of P-glycoprotein. There is also evidence for elevated levels of metal in the albumin leakage were rich in activated microglia, suggesting that microglia may directly affect BBB dysfunc-brain of PD subjects, suggesting a failure in transport systems. Metal ions released from dying neurons must tion.
be cleared by transport systems; otherwise, it may lead allowing them to diffuse transcellularly or require that proteins, genes, and cellular-based therapies be directly to further neurotoxicity, oxidative stress, and activation of microglia. Oxidative stress itself downregulates tight injected into the brain in order to be effective. If the BBB is disrupted in PD as recent literature suggests, junction protein occludin, affecting BBB permeability (63) .
then lipophilicity may not be a prerequisite for treatment and novel therapeutic strategies can emerge. Moreover, The proinflammatory cytokines TNF-α and VEGF also have angiogenic properties. Investigators have if the BBB disruption in PD is punctate and associated with areas of neuroinflammation as our data suggest, shown an increase in vascular density, or microangiogenesis, in the SNpc of PD patients and nonhuman pri-then targeted drug delivery can be achieved. mates (11, 36) . In addition, microangiogenesis was found IMPLICATIONS OF BBB DYSFUNCTION in close proximity to neuronal damage. The increase in IN DISEASE PROGRESSION vessels was highly correlated with increases in VEGF AND DRUG THERAPY expression, indicating that there was neovascularization Assuming that BBB dysfunction is a component of and not just an increase in blood vessel size (9) . We both AD and PD creates a number of new implications have also shown high degree of angiogenic vessels in in understanding of the disease process as well as curspecific regions of the brain in PD subjects (29) . Neorent and future drug therapies (Table 1 ). There has been vascularization may promote removal of cellular debris no adequate explanation for the progressive nature of and provide support and nutrients to degenerating areas; these disorders. The most widely held assumption is that however, these immature blood vessels are leaky and neuroinflammatory processes somehow become self-perpetmay also allow drugs, toxin, and peripheral immune uating, leading to progressive neuronal loss. However, cells to infiltrate and further exacerbate the disease. Evidence of angiogenesis, increased entry of drugs into the brain that normally do not enter, and passage of large (38, 68) .
VCAM increased increased
All of these treatment strategies have been guided by E-selectin increased unknown the notion that the BBB is intact in PD patients. There-Permeability increased increased fore, current therapeutics require drugs to be lipophilic, inducing neuroinflammation is not adequate because AD region, but the nanoparticle could compete for ICAM-1 binding with the leukocytes, possibly reducing leukocyte and PD animal models exhibiting neuroinflammation do not have progressive neuronal loss, arguing the involve-extravasation. Nanoparticles could also be targeted to the integrin αvβ3 located on vessels actively undergoing ment of other factors. If the BBB is disrupted, then elements of the peripheral immune system might serve as angiogenesis. These vessels are not only leaky, allowing nanoparticles to enter the brain paracellularly, but parti-another factor in disease progression in some patients. As reviewed above, there is growing evidence of the cles could also bind to the integrin and disrupt angiogenesis (74). involvement of components of the peripheral immune system in PD and AD patients. We published a series of If BBB dysfunction contributes to disease progression and/or compromises disease treatment, therapeutic studies suggesting the involvement of a dopamine neuron antibody that was identified in a large number of interventions designed to repair barrier function would be beneficial. Hydrocortisone has been shown to upreg-PD patients (21, 22, 27) . Other groups have characterized peripheral humoral immune changes in PD patients ulate occludin, which was accompanied by a threefold enhancement of transendothelial electrical resistance in (3, 39) . Whether these humoral immune changes reflect an infectious agent involved with etiology, a peripheral an in vitro BBB model (40) , indicating that hormones play an important role in maintenance of the BBB. Ef-aspect of the disease unrelated to CNS degeneration, or a response to central degeneration is unknown.
forts have also been made to reduce microglia activation, which in turn would reduce BBB dysfunction. Because it is becoming increasingly clear that there are regional differences to barrier function (6, 52) , this
Minocycline, a tetracycline that inhibits microglia activation, administered in animal models of AD and PD dynamic heterogeneity may be the contributing factor to the selective neurodegenerative processes that underlie showed reduction in proinflammatory cytokines and blocked neurotoxin-induced cell death in rats (15) and AD and PD. Polymorphisms of P-glycoprotein are present in the population (42) ; the same may hold true for is now in clinical trials.
As there are genetic mutations in proinflammatory other transport proteins, especially in disease, and would contribute to the heterogeneous nature of the BBB. molecules, amyloid protein, parkin, and many other enzymes, there may be genetic mutations in the proteins There may be less P-glycoprotein in the SNpc of PD or hippocampus of AD, but more in the parietal lobe, constituting the BBB endothelial cells. A genetic mutation in occludin or claudins may genetically predispose attributing the limited accumulation of toxin, β-amyloid, or drug in those regions of the brain. Additionally, if an individual to neurodegenerative disease. Nicoll et al. found that simultaneous inheritance of the IL-1β-889 areas of inflammation produce punctate BBB dysfunction, then drug entry into brain would be varied, leading and IL-1β + 3953 alleles increased the odds ratio for developing AD to 10.8; meaning that an individual has to varied side effects (20, 126) . In addition, punctate areas of leakage would allow water-soluble neurotoxins to 10.8 times greater risk than an individual of the same age without those alleles (84). If this is the case, siRNA enter the brain readily. It is critical to appreciate that regional barrier disruption in AD and PD contributes to or microRNA may be tools that could interfere with protein expression. If there was a genetic mutation in any therapeutic delivery and toxin exposure. Moreover, a compromised BBB would create innovative strategies protein that was permissive for disease progression, then siRNAs could interfere with the gene translation so the for targeted therapies.
Neuropeptides are attractive pharmacological agents. dysfunctional product was not made. Then, a vector containing the normal encoding gene could be delivered, Due to their small size, they would be able to enter areas of BBB disruption and interfere with β-amyloid deposi-allowing for the functional protein to be made. The alterations of the BBB in AD and PD, both as contributing tion. However, a small clinical trial utilizing neuropeptides showed marginal cognitive improvements, but had factors to the development and progression of disease and in its responses to disease, indicate that the BBB is severe toxic side effects (25) , suggesting that maybe these peptides were not only getting in through leaky a therapeutic target unto itself and not just an obstacle to overcome for CNS drug delivery. tight junctions, but also through transporter or vesicular uptake mechanisms. Instead, neuropeptides or nanopar-CONCLUSION ticles could be targeted to areas of the brain that are degenerating by targeting proteins on the BBB that are Once considered an impediment, the BBB can now be exploited to deliver appropriate drugs for neurologi-altered in specific areas due to specific neurodegeneration and inflammatory responses. For example, a particle cal conditions. The role the BBB plays in diseases, such as AD and PD, will assist researchers in devising new could be targeted to ICAM-1, a molecule upregulated in inflammation that mediates leukocyte attachment, a and innovative therapies. Recent studies have illustrated the complexity of the BBB in both large-scale central necessary first step for leukocytes extravasation. Not only would the drug be delivered only to the inflamed changes and local microenvironmental changes. The 
